The ATB200-02 study is an international, multi-center, study in adult subjects with Pompe disease. The purpose of this study is to find out if AT2221 can be safely used with ATB200 and will increase ATB200 in the bloodstream.


The PROPEL study is evaluating the effects of an investigational treatment regimen (AT-GAA co-administration) in adult study participants living with Pompe Disease.

Website coming soon.